BBO-11818, an orally bioavailable, highly potent and non covalent pan-KRAS inhibitor demonstrates robust anti-tumor activity in KRASG12D and KRASG12V preclinical models

BBO-10203, an orally bioavailable small molecule that disrupts the RAS:PI3Kα interaction leading to pAKT and tumor growth inhibition in models of breast, lung and colorectal cancer